Molecular Design and Clinical Development of VEGFR Kinase Inhibitors

Publisher： Bentham Science Publishers

E-ISSN： 1873-4294|7|14|1379-1393

ISSN： 1568-0266

Source： Current Topics in Medicinal Chemistry, Vol.7, Iss.14, 2007-07, pp. : 1379-1393

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Development of Vascular Endothelial Growth Factor Receptor (VEGFR) Kinase Inhibitors as Anti-Angiogenic Agents in Cancer Therapy

By  

Current Medicinal Chemistry, Vol. 11, Iss. 6, 2004-03 ,pp. : 731-745

Bentham Science Publishers

Access to resources Recommend Favorite

Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents

By Laird A Douglas   Cherrington Julie M  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 1, 2003-01 ,pp. : 51-64

Informa Healthcare

Access to resources Recommend Favorite

Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials

By  

Current Pharmaceutical Design, Vol. 18, Iss. 20, 2012-07 ,pp. : 2921-2935

Bentham Science Publishers

Access to resources Recommend Favorite

The Design, Structure, and Clinical Update of Small Molecular Weight Matrix Metalloproteinase Inhibitors

By  

Current Medicinal Chemistry, Vol. 11, Iss. 22, 2004-11 ,pp. : 2911-2977

Bentham Science Publishers

Access to resources Recommend Favorite

Recent Progress of Small Molecular VEGFR Inhibitors as Anticancer Agents

By  

Mini Reviews in Medicinal Chemistry, Vol. 11, Iss. 1, 2011-01 ,pp. : 18-31

Bentham Science Publishers

Access to resources Recommend Favorite